Search research articles
Contact Us
Filters
Showing results (101-110 of 145) with videos related to
Page
of 15
Sort By:
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology
|
May 19, 2023
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome
John P Thomson, Robert L Hollis, Juliette van Baal, et al.
British Journal of Cancer
|
October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
JAMA Oncology
|
March 17, 2023
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
Susana Banerjee, Gaia Giannone, Andrew R Clamp, et al.
Gynecologic Oncology
|
April 6, 2024
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Robert L Hollis, Richard Elliott, John C Dawson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Cancer Letters
|
June 1, 2019
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
Caroline Kreuzinger, Isabel von der Decken, Andrea Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 145) with videos related to
Sort By:
Page
of 15
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology
|
May 19, 2023
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome
John P Thomson, Robert L Hollis, Juliette van Baal, et al.
British Journal of Cancer
|
October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
JAMA Oncology
|
March 17, 2023
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
Susana Banerjee, Gaia Giannone, Andrew R Clamp, et al.
Gynecologic Oncology
|
April 6, 2024
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
Robert L Hollis, Richard Elliott, John C Dawson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Cancer Letters
|
June 1, 2019
Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
Caroline Kreuzinger, Isabel von der Decken, Andrea Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Page
of 15